-
Solana Company approves $100 million stock repurchase program
-
Solana Company files to cease Canadian reporting requirements
-
Solana Company adds Pantera Capital partner to board
-
Solana Company increases SOL holdings to 2.3 million tokens
-
Solana Company proceeds with share registration amid market volatility
-
Helius Medical files to register 155 million shares for resale
-
Solana Company selects BitGo as custodian for SOL treasury holdings
-
Solana Company adds Coinbase, BitGo and Anchorage Digital as custodians
-
HSDT reports holding over 2.2 million SOL tokens worth $525 million
-
Helius Medical Technologies (HSDT) files mixed shelf
-
Helius raises over $500 million to launch Solana treasury strategy
-
Helius Medical regains compliance with Nasdaq listing requirements
-
Helius Medical Technologies (HSDT) announces 1-for-50 reverse split
-
Helius Medical Technologies (HSDT) Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
-
Helius Medical Technologies (HSDT) Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator Device
-
Helius Medical Technologies (HSDT) Regains Nasdaq Compliance
-
Helius Medical Technologies (HSDT) Announces Reimbursement by Major Healthcare Provider for its PoNS Device
-
Helius Medical Technologies (HSDT) Announces 1:15 Reverse Share Split
-
Helius Medical Technologies (HSDT) Files for 6.21M Share Offering by Selling Stockholders
-
Helius Medical Technologies (HSDT) Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
-
Helius Medical Technologies (HSDT) Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy on Gait Deficit Improvement in Multiple Sclerosis from the PoNS Therapeut
-
Helius Medical Technologies (HSDT) Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
-
Helius Medical Technologies (HSDT) Announces First Portable Neuromodulation Stimulator System Sale to the Veterans Affairs (VA) Healthcare System
-
Helius Medical Technologies (HSDT)Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator Device
-
Maxim Group Downgrades Helius Medical Tech (HSDT) to Hold
-
Helius Medical Technologies (HSDT) Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator Controller and Mouthpiece
-
Helius Medical Technologies (HSDT) Announces Positive Preliminary Results of the PoNSTEP Study

